Journal
NATURE REVIEWS CANCER
Volume 12, Issue 4, Pages 265-277Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3258
Keywords
-
Categories
Funding
- US National Institutes of Health [P01 CA084514, U19 AIO57234, R01 CA089440, CA078846, CA140602]
- Dana Foundation
- Susan Komen Foundation
- Baylor Health Care System
- Baylor Health Care System Foundation
- ANRS
- INSERM
Ask authors/readers for more resources
Cancer immunotherapy attempts to harness the power and specificity of the immune system to treat tumours. The molecular identification of human cancer-specific antigens has allowed the development of antigen-specific immunotherapy. In one approach, autologous antigen-specific T cells are expanded ex vivo and then re-infused into patients. Another approach is through vaccination; that is, the provision of an antigen together with an adjuvant to elicit therapeutic T cells in vivo. Owing to their properties, dendritic cells (DCs) are often called 'nature's adjuvants' and thus have become the natural agents for antigen delivery. After four decades of research, it is now clear that DCs are at the centre of the immune system owing to their ability to control both immune tolerance and immunity. Thus, DCs are an essential target in efforts to generate therapeutic immunity against cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available